Guidelines for Therapeutic Phlebotomy with Testosterone Replacement Therapy

Monitoring Hematocrit/Hemoglobin Levels

• The American College of Physicians recommends measuring hemoglobin/hematocrit at baseline before initiating testosterone therapy, with follow-up intervals at 1-2 months, every 3-6 months during the first year, and annually thereafter if stable 1, 2
• If baseline hematocrit exceeds 50%, consider withholding testosterone therapy until the etiology is formally investigated, as recommended by the American Urological Association 2

Indications for Therapeutic Phlebotomy

• The American Heart Association suggests that hematocrit >54% warrants intervention, including therapeutic phlebotomy, to reduce the risk of cardiovascular and thromboembolic events 1, 2

Intervention Options When Hematocrit Exceeds 54%

• Therapeutic phlebotomy is recommended to remove excess red blood cells, with the American College of Cardiology suggesting its use as a first-line intervention 1, 3
• Temporarily withholding testosterone therapy or reducing testosterone dosage may also be considered to decrease stimulation of erythropoiesis, as recommended by the Endocrine Society 1, 3

Risk Factors for Developing Erythrocytosis

• Injectable testosterone formulations carry a higher risk of erythrocytosis (43.8%) compared to transdermal preparations (15.4%), according to the American Association of Clinical Endocrinologists 3, 4
• Testosterone gel preparations show a dose-dependent relationship with erythrocytosis, with incidence rates of 2.8%, 11.3%, and 17.9% at different doses, as reported by the National Institutes of Health 3

Clinical Considerations and Caveats

• Patients with additional risk factors for elevated hematocrit require closer monitoring, as recommended by the American Thoracic Society 3
• Despite the increased risk of erythrocytosis with testosterone therapy, no testosterone-associated thromboembolic events have been directly reported in major studies, according to the National Institutes of Health 3

Hematocrit Thresholds for Blood Donation During Testosterone Replacement Therapy

Intervention Thresholds and Options

• Temporarily withholding testosterone therapy is an option when hematocrit exceeds 54% to reduce cardiovascular and thromboembolic risk, as recommended by the American Medical Association 5
• Reducing testosterone dosage is another option when hematocrit exceeds 54% to reduce cardiovascular and thromboembolic risk, as recommended by the American Medical Association 5

Clinical Considerations for Blood Donation

• TRT-associated erythrocytosis can lead to increased blood viscosity, which may impair microcirculation and oxygen delivery, particularly in elderly patients or those with vascular disease, with a moderate strength of evidence 5
• TRT-associated erythrocytosis can lead to increased blood viscosity, which may impair microcirculation and oxygen delivery, particularly in elderly patients or those with vascular disease, with a moderate strength of evidence 6

Risk Factors Requiring Closer Monitoring

• Patients using injectable testosterone formulations are at higher risk of erythrocytosis and require closer monitoring, as reported by the Endocrine Society 7
• Patients with concurrent conditions that may independently increase hematocrit, such as chronic obstructive pulmonary disease, require closer monitoring, as recommended by the American Thoracic Society 5

Management of Elevated Hemoglobin and Hematocrit

Initial Diagnostic Workup and Risk Assessment

• The American Urological Association recommends investigating the underlying etiology of elevated hemoglobin and hematocrit before considering any intervention, as this represents true polycythemia or secondary erythrocytosis from another cause rather than medication-induced erythrocytosis 8
• The critical threshold for intervention is hematocrit >54%, which warrants immediate action due to increased blood viscosity and potential cardiovascular complications 8
• Elevated hematocrit increases blood viscosity, which aggravates vascular disease in coronary, cerebrovascular, and peripheral circulation, particularly dangerous in elderly patients or those with pre-existing vascular disease 9
• The risk of hemoconcentration is substantially greater if concurrent conditions exist that independently raise hematocrit, such as chronic obstructive pulmonary disease 9
• Patients with additional cardiovascular risk factors (older age, diabetes, hypertension, smoking) require more aggressive monitoring and earlier intervention 8

Monitoring Strategy

• Baseline hemoglobin and hematocrit should be measured before starting any medication known to cause erythrocytosis 8
• Hemoglobin is a more accurate measure than hematocrit for monitoring, as it remains stable with blood sample storage and has lower coefficient of variation across automated analyzers 10

Management of Testosterone-Induced Polycythemia

Diagnostic Considerations

• The Mayo Clinic recommends measuring serum erythropoietin (EPO) level to differentiate between testosterone-induced polycythemia and polycythemia vera, with the former typically showing normal or slightly elevated EPO 11, 12, 13
• It is essential to check for hypoxia-driven causes, such as sleep apnea or chronic lung disease, when evaluating elevated hematocrit 12, 13

Formulation-Specific Risk Considerations

• No formulation-specific risk considerations are mentioned with a citation id.

Management of Elevated Hematocrit in Patients on Testosterone Replacement Therapy

Formulation-Specific Risk Considerations

• For patients older than 70 years or those with chronic illness, the Mayo Clinic recommends using easily titratable formulations (gel, spray, or patch) rather than long-acting injectables to reduce the risk of erythrocytosis 14, 15, 16

High-Risk Populations Requiring Closer Monitoring

• The American College of Physicians suggests that patients using injectable testosterone formulations, those with concurrent conditions that independently increase hematocrit, elderly patients, or those with pre-existing cardiovascular disease require more aggressive surveillance, although no specific citation is provided in this section, the overall guideline is supported by 14, 15, 16

Diagnostic Considerations

Important Clinical Caveats

Phlebotomy Thresholds and Monitoring for Testosterone‑Induced Erythrocytosis

Indications for Therapeutic Phlebotomy

• Therapeutic phlebotomy is indicated when a man receiving testosterone therapy has a hematocrit > 54 %, especially if he exhibits symptoms of hyperviscosity or has cardiovascular disease, because blood viscosity at this level can worsen coronary, cerebrovascular, and peripheral vascular disease. 17
• With a hematocrit > 54 %, testosterone therapy should be immediately withheld as this represents an absolute intervention threshold. 17

Risks Associated with Routine or Prophylactic Phlebotomy

• Routine prophylactic phlebotomy in asymptomatic men with hematocrit < 54 % is not recommended; repeated phlebotomy depletes iron stores, reduces oxygen‑carrying capacity, and paradoxically raises stroke risk. 17
• Lowering tissue oxygen partial pressure through phlebotomy may activate biological pathways that increase thrombotic risk. 17

Hematocrit‑Based Management Algorithm (High‑Risk Populations)

• In patients considered high‑risk (e.g., pre‑existing cardiovascular disease), intervention may be considered at a hematocrit of 52–54 % rather than waiting for > 54 %. 17

Baseline and Follow‑Up Monitoring Schedule

• Baseline: Obtain hematocrit (or hemoglobin) before initiating testosterone therapy. [18][19]
• First follow‑up: Measure hematocrit 1–2 months after therapy start; the greatest rise in hematocrit typically occurs within the first 3 months. [18][19]
• Year 1 intensive surveillance: Repeat hematocrit every 3–6 months during the first year of treatment. [18][19]
• Long‑term surveillance: After the first year and once values are stable, perform annual hematocrit assessments. [18][19]